|
Michael Fons, Ph.D., MBA, joined Inovio in June 2004. Dr. Fons has been instrumental in defining Inovio's corporate strategy relating to DNA vaccines and DNA delivery, including assisting in securing DNA-related license agreements, acquiring valuable intellectual property assets, and establishing a strong standard for the management of Inovio's corporate relationships. Prior to joining Inovio, Dr. Fons held business development roles with Vical, Valentis, and GeneMedicine. Dr. Fons completed his doctoral work in virology at the University of Texas Medical Branch in Gaveston and is an Adjunct Associate Professor of Microbiology and Immunology with the University of Texas Medical Branch. He has given numerous presentations at national and international conferences and has published extensively in scientific journals and books. | 